Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Denali Therapeutics Inc (NQ: DNLI )

31.24 +1.81 (+6.15%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 1, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 492,902
Open 29.55
Bid (Size) 25.00 (1)
Ask (Size) 32.95 (2)
Prev. Close 29.43
Today's Range 28.94 - 31.53
52wk Range 20.24 - 79.50
Shares Outstanding 121,640,069
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
R&D Efforts for Central Nervous System (CNS) Therapeutics Have Resulted in Hopeful Novel Drug-Delivery Solutions
Palm Beach, FL – June 29 2022 – FinancialNewsMedia.com News Commentary – In the central nervous system (CNS) therapeutics market, large and small pharmaceutical companies are highly investing in the... 
Via FinancialNewsMedia
Rising Cases Of Mental Health Disorders of Stress, Anxiety & Addiction Fueling Need for Central Nervous System Therapeutics
Palm Beach, FL – June 7, 2022 – FinancialNewsMedia.com News Commentary – The global Central Nervous System (CNS) treatments and its market revenues had been steadily growing pre-pandemic and are still... 
Via FinancialNewsMedia
Exposures COVID-19

Performance

YTD
-33.91%
-33.91%
1 Month
+30.77%
+30.77%
3 Month
-10.77%
-10.77%
6 Month
-29.96%
-29.96%
1 Year
-60.07%
-60.07%

More News

Read More
Benzinga's Top Ratings Upgrades, Downgrades For June 23, 2022
Via Benzinga
Revenues From Treatment of Rare Neurological Disorders Worldwide Are Poised to Surpass $12 Billion in 2026
Via FinancialNewsMedia
4 Undervalued Biotech Stocks to Add to Your Buy List
Via InvestorPlace
AbbVie Stock Breaks Its Stride As Key Executive Departs For Flagship
Via Investor's Business Daily
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
R&D Efforts for Alzheimer’s Therapies on the Rise with over 120 Drugs in Development
Via FinancialNewsMedia
7 F-Rated Stocks to Avoid During the Downturn
Via InvestorPlace
Denali Receives Formal Letter Regarding FDA Hold On Alzheimer's Potential Program
Via Benzinga
The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly
Via Benzinga
48 Biggest Movers From Yesterday
Via Benzinga
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Mid-Afternoon Market Update: Nasdaq Dips 250 Points; Taiwan Semiconductor Shares Gain
Via Benzinga
Denali Stock Tumbles; Why Biogen Isn't The Only Alzheimer's Play Under Pressure
Via Investor's Business Daily
26 Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Mid-Morning Market Update: Markets Rise; Delta Air Lines Profit Tops Estimates
Via Benzinga
FDA Places Clinical Hold On Denali's Alzheimer's Potential Program
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Jim Cramer Says This Stock Is 'Really Cheap'
Via Benzinga
Intranasal Ketamine Garnering A lot of Attention as an Effective Treatment For Depression
Via FinancialNewsMedia
Exposures COVID-19
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
Via Benzinga
Denali Highlights Encouraging Early Data, Update For Amyotrophic Lateral Sclerosis Program
Via Benzinga
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.